Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Date publication

janvier 2026

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Harba A, Moinard-Butot F, Auclin E, Barthélémy P, Noel J, Dumont C, Gauthier H, Huillard O, Jaffrelot L, Seisen T, Joly C, Tournigand C, Bennamoun M, Roulleaux-Dugage M, Cancel M, Heurtier V, Lardjani H, Oudard S, Thibault C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41654457

Résumé

Bone metastases occur in one third of patients with metastatic clear cell renal cell carcinoma (mccRCC) and are associated with poor prognosis. Optimal first-line treatment for this subgroup of patients remains undefined.

Mots clés

Bone metastases, Bone-targeting agents, Clear Cell renal Cell Carcinoma, First-line treatment combinations, Skeletal-related events

Référence

Clin Genitourin Cancer. 2026 01 14;:102506